REG - Arecor Therapeutics - Arecor Continues Collaboration with Lilly

Arecor TherapeuticsAnnouncement

29/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231129:nRSc9702Ua&default-theme=true

RNS Number : 9702U  Arecor Therapeutics PLC  29 November 2023

 

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR CONTINUES COLLABORATION WITH LILLY

Development of an enhanced formulation of Lilly proprietary product using
Arecor's formulation technology platform Arestat™

 

Cambridge, UK, 29 November 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that it has signed a further collaboration agreement with Eli
Lilly and Company ("Lilly").

 

Under the terms of this agreement, Arecor will use its proprietary formulation
technology platform, Arestat™, to develop a novel liquid formulation of one
of Lilly's products with enhanced properties. Lilly will fund the development
work and has the option to acquire the rights to the new formulation and newly
created intellectual property under a technology licensing model to further
develop and commercialise the product.

 

Sarah Howell, Chief Executive Officer of Arecor, said: "Building on what has
already proven to be a successful partnership, we are delighted that Lilly has
turned to us once again for our innovative technology and expertise. With 11
technology partnerships from new and existing partners signed since our IPO,
our partnered portfolio continues to expand, further demonstrating the
strength of our know-how and expertise, and recognising Arecor as a partner of
choice for enhanced safe, efficacious and more convenient treatments that
improve patient outcomes. These partnerships also provide near term revenue
plus upside potential from future licensing opportunities."

 

This announcement contains inside information for the purposes of the
retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK
MAR").

 

-ENDS-

 

 

 

 

 

For more information, please contact:

 

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 ICR Consilium                                    Tel: +44 (0) 20 3709 5700

 Chris Gardner, David Daley, Lindsey Neville      Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio. For further details please see our website, www.arecor.com
(http://www.arecor.com) .

 

About Arestat™

Arestat™ is Arecor's innovative and proprietary formulation technology
platform developed from novel insights into molecular interactions and is
broadly applicable to a wide range of therapeutic products, notably

antibodies, peptides, biologics and vaccines. Arecor applies the Arestat™
technology to deliver superior reformulations of existing products and new
products in development, with enhanced properties that would otherwise be
unachievable. Benefits of these novel formulations can range from improved
shelf-life, previously unattainable concentrations, greater patient
convenience and superior therapeutic profiles.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBPBPTMTBTBRJ